查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1400724

口服聚合物製劑的全球市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按適應症、按最終用戶、按地區

Oral Macromolecular Formulation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 158 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

全球口服聚合物藥物市場正經歷顯著成長，預計2024年銷售額將達到1,800萬美元。預計該市場將維持 7% 的強勁複合年增長率 (CAGR)，到 2031 年底估計估值將達到約 2,800 萬美元。

口服藥物遞送因其優點而成為最理想的途徑，包括固體製劑的可能性，例如延長的保質期、持續的分佈和增強的免疫反應。

口服聚合物製劑可以減少與注射相關的許多風險，例如針傷、疼痛和針刺傷。美國每年約有 385,000 起醫護人員遭受銳器傷害，凸顯了更安全替代方案的重要性。由於注射帶來的不適，兒科患者對口服製劑的需求尤其高。

口服給藥因其非侵入性、患者依從性和易用性而成為最常見的藥物傳遞方法。口服給藥對於老年體弱的患者尤其重要，他們可以自行給藥而無需幫助。

由於其成本效益，口服聚合物製劑的需求量很大，特別是在低收入地區。專門從事口服聚合物製劑的研究人員和合約製造商致力於透過提供新穎實用的單劑量製劑來簡化患者的生活。

全球糖尿病發生率的增加正在推動對口服聚合物製劑的需求，因為糖尿病患者可能需要胰島素治療。與靜脈注射相比，胰島素等生物分子的口服製劑具有潛在的優勢，靜脈注射可能會給患者帶來不舒服和挑戰。

製藥商正在積極探索各種方法來增強生物製劑的口服給藥，以克服酵素降解和酸降解。口服聚合物製劑的吸收面臨生理障礙，許多聚合物容易被消化酵素快速降解。胃酸鹼度也影響藥物吸收。

由於技術進步、專利批准增加以及藥物傳輸奈米技術應用的區域研究，美國市場正在不斷成長。德國市場預計將繼續成長，積極的研發活動集中在新的藥物輸送系統。

該報告考察了全球口服聚合物藥物市場，並提供了市場概況，包括按適應症、最終用戶、地區劃分的趨勢以及進入市場的公司的競爭趨勢。

目錄

第一章執行摘要

第二章市場概況

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • COVID-19 影響分析
  • 烏克蘭與俄羅斯衝突的影響
  • 經濟概況
  • PESTLE分析

第三章 2018-2031年全球口服高分子藥物市場展望

  • 2018-2031 年全球口服聚合物藥物市場前景（按適應症、價值（百萬美元））
  • 全球口服聚合物藥物市場前景（按最終用戶劃分），價值（百萬美元），2018-2031 年
  • 2018-2031 年全球口服聚合物藥物市場前景（按地區、價值（百萬美元））

第四章 2018-2031年北美口服高分子藥物市場展望

第五章 2018-2031年歐洲口服高分子藥物市場前景

第六章 2018-2031年亞太口服高分子藥物市場展望

第七章 2018-2031 拉丁美洲口服聚合物藥品市場展望

第8章 2018-2031年中東及非洲口服高分子藥物市場前景

第9章 競爭格局

  • 按製造商和最終用戶劃分的熱圖
  • 2023 年公司市場份額分析
  • 比賽儀表板
  • 公司簡介
    • Catalent, Inc
    • Diabetology Ltd
    • UPM Pharmaceuticals

第10章附錄

簡介目錄

The global Oral Macromolecule Formulation Market is experiencing remarkable growth, with revenues reaching US$ 18 million in 2024. Market analysts anticipate a steady Compound Annual Growth Rate (CAGR) of 7%, propelling the market to an estimated valuation of approximately US$ 28 million by the end of 2031.

Oral Delivery: The Preferred Route

Oral drug delivery has emerged as the most desirable route due to its advantages, including the potential for solid formulations with extended shelf life, continuous distribution, and enhanced immune response.

The numerous risks associated with injections, such as needle-related injuries, pain, and needle stick injuries, can be mitigated by oral macromolecule formulations. Approximately 385,000 sharp injuries occur among healthcare workers in the US each year, highlighting the importance of safer alternatives. Pediatric patients, in particular, have a high demand for oral formulations due to the discomfort associated with injections.

Growing Preference for Oral Administration

Oral administration has become the most popular method of drug delivery due to its non-invasiveness, patient compliance, and ease of use. It is especially crucial for elderly and physically fragile individuals, enabling self-administration of medications without the need for assistance.

Affordability and Accessibility

Oral macromolecule formulations are in significant demand, particularly in low-income regions, owing to their cost-effectiveness. Researchers and contract manufacturers specializing in oral macromolecule formulations are dedicated to simplifying patients' lives by offering novel and practical single-unit dosage forms.

Diabetes and Oral Macromolecular Formulations

The global rise in diabetes has driven the demand for oral macromolecular formulations, as diabetic patients may require insulin therapy. The oral formulation of biomolecules like insulin offers potential advantages over intravenous administration, which can be uncomfortable and challenging for patients.

Market Growth Drivers

Introduction of Novel Drug Delivery Systems: Pharmaceutical manufacturers are actively exploring various methods to enhance the oral administration of biologics, aiming to overcome enzymatic and acidic breakdown.

Challenges in Market Growth

Drawbacks and Poor Absorption: The absorption of oral macromolecule formulations faces physiological barriers, and many macromolecules are susceptible to rapid degradation by digestive enzymes. Gastric pH can also impact drug absorption.

Booming U.S. Market

The United States market is experiencing growth due to technological advancements, increased patent approvals, and regional research on nanotechnology applications for drug delivery.

Lucrative Market in Germany

Germany's market is set to advance with growing R&D activities focused on novel drug delivery systems.

China's Research Funding

The National Natural Science Foundation of China has funded various studies on the novel oral delivery of protein and peptide drugs, aligning with the booming market for these pharmaceuticals.

Competitive Landscape

Top pharmaceutical companies are forming strategic alliances with providers of oral macromolecule formulations, and the global market is expected to expand due to the rising demand for pharmaceutical outsourcing.

Key Companies Covered:

  • Catalent, Inc
  • Diabetology Ltd
  • UPM Pharmaceuticals

Market Segmentation

Indication:

  • Inflammatory Bowel Disorder

Crohn's Disease

Ulcerative Colitis

  • Diabetes
  • Others

End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Oral Macromolecular Formulation Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 3.1. Global Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Inflammatory Bowel Disorder
        • 3.1.1.1.1. Crohn's Disease
        • 3.1.1.1.2. Ulcerative Colitis
      • 3.1.1.2. Diabetes
      • 3.1.1.3. Others
  • 3.2. Global Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Biopharmaceutical Companies
      • 3.2.1.2. Academic and Research Institutes
  • 3.3. Global Oral Macromolecular Formulation Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 4.1. North America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Inflammatory Bowel Disorder
        • 4.1.1.1.1. Crohn's Disease
        • 4.1.1.1.2. Ulcerative Colitis
      • 4.1.1.2. Diabetes
      • 4.1.1.3. Others
  • 4.2. North America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Biopharmaceutical Companies
      • 4.2.1.2. Academic and Research Institutes
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.3.1.2. U.S. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.3.1.3. Canada Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.3.1.4. Canada Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 5.1. Europe Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Inflammatory Bowel Disorder
        • 5.1.1.1.1. Crohn's Disease
        • 5.1.1.1.2. Ulcerative Colitis
      • 5.1.1.2. Diabetes
      • 5.1.1.3. Others
  • 5.2. Europe Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Biopharmaceutical Companies
      • 5.2.1.2. Academic and Research Institutes
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.2. Germany Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.3. U.K. Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.4. U.K. Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.5. France Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.6. France Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.7. Italy Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.8. Italy Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.9. Turkey Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.10. Turkey Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.11. Russia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.12. Russia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Inflammatory Bowel Disorder
        • 6.1.1.1.1. Crohn's Disease
        • 6.1.1.1.2. Ulcerative Colitis
      • 6.1.1.2. Diabetes
      • 6.1.1.3. Others
  • 6.2. Asia Pacific Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Biopharmaceutical Companies
      • 6.2.1.2. Academic and Research Institutes
    • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.2. China Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.3. Japan Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.4. Japan Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.5. South Korea Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.6. South Korea Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.7. India Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.8. India Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 7.1. Latin America Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Inflammatory Bowel Disorder
        • 7.1.1.1.1. Crohn's Disease
        • 7.1.1.1.2. Ulcerative Colitis
      • 7.1.1.2. Diabetes
      • 7.1.1.3. Others
  • 7.2. Latin America Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Biopharmaceutical Companies
      • 7.2.1.2. Academic and Research Institutes
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.2. Brazil Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.3. Mexico Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.4. Mexico Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.5. Argentina Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.6. Argentina Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Oral Macromolecular Formulation Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Inflammatory Bowel Disorder
        • 8.1.1.1.1. Crohn's Disease
        • 8.1.1.1.2. Ulcerative Colitis
      • 8.1.1.2. Diabetes
      • 8.1.1.3. Others
  • 8.2. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Biopharmaceutical Companies
      • 8.2.1.2. Academic and Research Institutes
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Oral Macromolecular Formulation Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.2. GCC Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.3. South Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.4. South Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.5. Egypt Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.6. Egypt Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.7. Nigeria Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.8. Nigeria Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Oral Macromolecular Formulation Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Oral Macromolecular Formulation Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs by End User Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Catalent, Inc
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Diabetology Ltd
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. UPM Pharmaceuticals
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations